| Bid | 7.4 |
| Market Cap | 244.25M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.14 |
| PE Ratio (ttm) | 54.79 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.25 |
| Volume | 78,674 |
| Avg. Volume (20D) | 87,678 |
| Open | 7.79 |
| Previous Close | 7.77 |
| Day's Range | 7.50 - 7.86 |
| 52-Week Range | 7.15 - 13.77 |
| Beta | undefined |
About ZYXI
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by fiel...
Analyst Forecast
According to 2 analyst ratings, the average rating for ZYXI stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 82.53% from the latest price.
Next Earnings Release
Analysts project revenue of $53.29M, reflecting a 12.70% YoY growth and earnings per share of 0.1, making a 150.00% increase YoY.
4 weeks ago · proactiveinvestors.com
Zynex partners with VA to offer pain management solutions for veteransZynex Inc (NASDAQ:ZYXI) has announced a new partnership with Veterans Affairs Medical Centers (VAMCs) across the United States, a significant opportunity to expand the reach of its noninvasive medical...
1 month ago · proactiveinvestors.com
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMIZynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to em...
1 month ago · proactiveinvestors.com
Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeterZynex Inc (NASDAQ:ZYXI) has announced its membership in the Collaborative Community of the Open Oximetry Project as an industry member. This initiative, led by the University of California, San Franci...
1 month ago · proactiveinvestors.com
Zynex leverages multi-modality NexWave device to transform pain managementZynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, reimbursable solutions. While the company has successfully capitalized on th...
2 months ago · proactiveinvestors.com
Zynex sees pain management orders increase in Q3 following FDA approvalZynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net reven...
2 months ago · proactiveinvestors.com
Sales, strategy, and saving lives: A conversation with Zynex CEO Thomas SandgaardThomas Sandgaard is just getting started. The enigmatic “rockstar CEO” of pain management company Zynex Inc (NASDAQ:ZYXI) has worn many hats throughout his career: Sales leader, lead guitarist, footba...